A Phase I, Multiple-Dose, Open-Label, Crossover Study in Healthy Subjects to Assess the Effect of Dolutegravir (DTG) on the Pharmacokinetics (PK) of Cenicriviroc (CVC) and the Effect of CVC on the PK of DTG and on a Single Dose of Midazolam
Latest Information Update: 28 Jan 2014
At a glance
- Drugs Cenicriviroc (Primary) ; Dolutegravir; Midazolam
- Indications HIV-1 infections; Insomnia
- Focus Pharmacokinetics
- Sponsors Tobira Therapeutics
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Apr 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Apr 2013 New trial record